Agent Based Modeling of Atherosclerosis: A Concrete Help in Personalized Treatments
Atherosclerosis, a pathology affecting arterial blood vessels, is one of most common diseases of the developed countries. We present studies on the increased atherosclerosis risk using an agent based model of atherogenesis that has been previously validated using clinical data. It is well known that the major risk in atherosclerosis is the persistent high level of low density lipoprotein (LDL) concentration. However, it is not known if short period of high LDL concentration can cause irreversible damage and if reduction of the LDL concentration (either by life style or drug) can drastically or partially reduce the already acquired risk. We simulated four different clinical situations in a large set of virtual patients (200 per clinical scenario). In the first one the patients lifestyle maintains the concentration of LDL in a no risk range. This is the control case simulation. The second case is represented by patients having high level of LDL with a delay to apply appropriate treatments; The third scenario is characterized by patients with high LDL levels treated with specific drugs like statins. Finally we simulated patients that are characterized by several oxidative events (smoke, sedentary life style, assumption of alcoholic drinks and so on so forth) that effective increase the risk of LDL oxidation. Those preliminary results obviously need to be clinically investigated. It is clear, however, that SimAthero has the power to concretely help medical doctors and clinicians in choosing personalized treatments for the prevention of the atherosclerosis damages.
KeywordsFoam Cell Virtual Patient Foam Cell Formation Sedentary Life Style Arterial Blood Vessel
Unable to display preview. Download preview PDF.
- 1.Abbas, A.K., Lichtman, A.H., Pillai, S.: Cellular and molecular immunology, 6th edn. Saunders, Philadelphia (2007)Google Scholar
- 5.Brizzi, P., Isaja, T., D’Agata, A., Malaguarnera, A., Malaguarnera, M., Musumeci, S.: Oxidized LDL antibodies (OLAB) in patients with beta-thalassemia major. J. Atheroscler. Thromb. 9(3), 139–144 (2002)Google Scholar
- 9.Klimov, A.N., Nikul’cheva, N.G.: Lipid and Lipoprotein Metabolism and Its Disturbances. Piter Kom, St. Petersburg (1999)Google Scholar
- 13.Romero-Corral, A., Somers, V.K., Korinek, J., Sierra-Johnson, J., Thomas, R.J., Allison, T.G., Lopez-Jimenez, F.: Update in prevention of atherosclerotic heart disease: management of major cardiovascular risk factors. Rev. Invest. Clin. 58(3), 237–244 (2006)Google Scholar
- 15.Shaw, P.X., Hörkkö, S., Tsimikas, S., Chang, M.K., Palinski, W., Silverman, G.J., Chen, P.P., Witztum, J.L.: Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo.t Arterioscler. Thromb. Vasc. Biol. 21(8), 1333–1339 (2001)CrossRefGoogle Scholar
- 16.Shoji, T., Nishizawa, Y., Fukumoto, M., Shimamura, K., Kimura, J., Kanda, H., Emoto, M., Kawagishi, T., Morii, H.: Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 148(1), 171–177 (2000)CrossRefGoogle Scholar
- 18.Tinahones, F.J., Gomez-Zumaquero, J.M., Rojo-Martinez, G., Cardona, F., Esteva de Antonio, I.E., Ruiz de Adana, M.S., Soriguer, F.K.: Increased levels of anti-oxidized low-density lipoprotein antibodies are associated with reduced levels of cholesterol in the general population. Metabolism 51(4), 429–431 (2002)CrossRefGoogle Scholar
- 19.Tinahones, F.J., Gomez-Zumaquero, J.M., Garrido-Sanchez, L., Garcia-Fuentes, E., Rojo-Martinez, G., Esteva, I., Ruiz de Adana, M.S., Cardona, F., Soriguer, F.: Influence of age and sex on levels of anti-oxidized LDL antibodies and anti-LDL immune complexes in the general population. J. Lipid Res. 46(3), 452–457 (2005)CrossRefGoogle Scholar
- 20.Vinereanu, D.: Risk factors for atherosclerotic disease: present and future. Herz, Suppl. 3, 5–24 (2006)Google Scholar